Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care.

A Phase I Dose-Escalation and Metabolomics Study of Metformin Combined with Chemotherapy and/or Immunotherapy in Solid Malignancies



Phase: Phase I

Principal Investigator: Wasif Saif, M.D., MBBS

Karmanos Trial ID: 2024-050

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute - Detroit
• Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

Therapies: Biological Therapy

Drug: Metformin

Cancer Categories: Breast, Gastrointestinal, Gynecologic, Lung, and Skin

Eligibility Criteria

• Any advanced solid tumor with measurable disease per RECIST 1.1
• Patient must be a candidate for chemotherapy and/or immunotherapy
• Not currently taking metformin

Refer a Patient

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab Compared with Investigator's Choice of Chemotherapy (Paclitaxel, Nab-Paclitaxel or Gemcitabine + Carboplatin) in Combination with Pembrolizumab in Patients with PD-L1 positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TROPION-Breast05)

Phase: Phase III

Cancer Category: Breast

Principal Investigator: Jailan Elayoubi, M.D.

Karmanos Trial ID: 2024-049

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute - Detroit
• Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

Therapies: Chemotherapy

Eligibility Criteria

• Locally recurrent inoperable or metastatic triple-negative breast cancer
• PD-L1 positive (CPS ≥ 10) per PD-L1 (22C3) assay
• No prior chemotherapy for metastatic or locally recurrent inoperable breast cancer
• Eligible for paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin

Refer a Patient

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer



Phase: Phase II

Principal Investigator: Brian Yeh, M.D.

Karmanos Trial ID: 2021-056

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute at McLaren Bay Region
• Karmanos Cancer Institute at McLaren Central Michigan
• Karmanos Cancer Institute at McLaren Flint
• Karmanos Cancer Institute at McLaren Greater Lansing
• Karmanos Cancer Institute at McLaren Lapeer Region

Therapies: Proton Therapy, Radiation Therapy

Eligibility Criteria

• ER+ invasive ductal carcinoma and/or ductal carcinoma in situ
• Lumpectomy performed, with documented negative surgical margins by 0.2 cm or more
• Stage 0, I, II (Tis, T1, or T2 N0 M0); must be pN0
• Must be >= 50 years of age

Refer a Patient

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer



Phase: Phase III

Cancer Category: Breast

Principal Investigator: Jailan Elayoubi, M.D.

Karmanos Trial ID: S2206

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute - Detroit
• Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills
• Karmanos Cancer Institute at McLaren Greater Lansing

Therapies: Chemotherapy, Immunotherapy

Eligibility Criteria

• ER+/PR+/HER2- breast cancer, clinical stages II or III
• MammaPrint High Risk 2 result (testing provided during screening)
• No prior treatments; must be a candidate for doxorubicin, paclitaxel, and durvalumab therapy
• ECOG 0-2

Refer a Patient

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

Phase: Phase II

Principal Investigator: Najeeb Al Hallak, M.D.

Karmanos Trial ID: 2024-021

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute - Detroit
• Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

Therapies: Immunotherapy, Radiation Therapy

Eligibility Criteria

• Confirmed hepatocellular carcinoma by imaging with no evidence of extrahepatic disease
• Disease is not amenable to curative surgery, ablation, or transplantation
• Disease is amenable to complete treatment with TARE in one session, with no more than 70% of liver radiated
• Child-Pugh score class A

Refer a Patient

A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Phase: Phase I/II

Principal Investigator: Najeeb Al Hallak, M.D.

Karmanos Trial ID: 2022-069

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute - Detroit
• Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

Therapies: Biological Therapy, Immunotherapy

Eligibility Criteria

• Locally advanced or metastatic and unresectable hepatocellular carcinoma
• Child-Pugh class A or B7
• Cohort A: Objective progression on up to 3 prior lines of systemic therapy
• Cohort B: Objective progression following at least 2 cycles of first-line anti-PD-1/PDL1 monotherapy or combination therapy
• Cohort C: Naïve to systemic treatment for locally advanced or metastatic, and unresectable HCC

Refer a Patient

TheraBionic P1 Device for Patients with Advanced Hepatocellular Carcinoma (HCC) who Fail First and Second Line Therapy

Phase: Phase IV

Principal Investigator: Anthony Shields, M.D., Ph.D.

Karmanos Trial ID: 2024-074

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute - Detroit
• Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

Drugs: TheraBionic P1 Device

Eligibility Criteria

• Advanced hepatocellular carcinoma
• Failed at least two lines of therapy or are no longer eligible for any line of standard therapy
• Patient must be ≥ 22 years old

Refer a Patient

Increasing Knowledge and Interest in Cancer Clinical Trials

Applicable Disease Sites: Breast; Colon; Liver; Other Digestive Organ; Small Intestine; Stomach

Principal Investigator: Hayley Thompson

Karmanos Trial ID: 2019-137

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute - Detroit

Eligibility Criteria

• All adults aged 21 and older
• No cancer diagnosis required

Refer a Patient